No Yes Ok

Archive

« Older Entries Newer Entries »

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute M... Monday, December 3rd, 2018
Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reduction of bleeding events  ITP program expected to advance to Phase 3 with IV efgartigimod and Phase 2 [...]
LSP wins Lifestars Award for EU investment firm of the year Monday, November 19th, 2018
Celebrating success across life sciences   Amsterdam, The Netherlands, November 14, 2018 – LSP is pleased to announce that it has been recognised as the winner of the EU Investment Firm of the year at the 2 [...]
Simplify Medical Completes Enrollment in U.S. IDE Pivotal Trial of Simplify® Disc for Two-Level Cervical Disc Replacement Wednesday, November 14th, 2018
Sunnyvale, CA – November 14, 2018 – Simplify Medical Pty Ltd., maker of the Simplify® cervical artificial disc, today announced that it has completed the enrollment and treatment of all patients in its U.S. Inves [...]
LSP raises record €750 million in 10 months for life sciences innovations Monday, November 12th, 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe [...]
Immunic enters into a global option and license agreement with Daiichi Sankyo Monday, November 5th, 2018
Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease   IMU-856 is a new oral treatment option for ulcerative colit [...]
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Expos... Thursday, November 1st, 2018
Regulated information – Inside information   92% overall response rate with durability up to 14.4 months in ongoing analysis of Phase 1/2 trial   Updated results from Phase 1/2 trial of cusatuzumab in [...]
Product of LSP’s portfolio company GTX medical restores walking in humans with spinal cord injury Thursday, November 1st, 2018
Amsterdam, The Netherlands, November 1, 2018 – LSP’s portfolio company GTX medical is developing a groundbreaking product to restore walking in spinal cord injury patients. This week, two articles were published i [...]
argenx reports third quarter 2018 financial results and provides business update Thursday, October 25th, 2018
Breda, the Netherlands / Ghent, Belgium, October 25, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treat [...]
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC) Friday, September 28th, 2018
Arimoclomol was well-tolerated in patients with the rare disease NPC The NPC Phase II/III trial top-line results show a treatment benefit of arimoclomol over placebo on the primary endpoint 5-domain NPC Clin [...]
Merus Strengthens Team with Key Appointments Thursday, September 27th, 2018
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP, Investor Relations and Corporate Communications [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute... Monday, December 3rd, 2018
Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reduction of bleeding events  ITP program expected to advance to Phase 3 with IV efgartigimod and Phase 2 [...]
LSP wins Lifestars Award for EU investment firm of the year Monday, November 19th, 2018
Celebrating success across life sciences   Amsterdam, The Netherlands, November 14, 2018 – LSP is pleased to announce that it has been recognised as the winner of the EU Investment Firm of the year at the 2 [...]
Simplify Medical Completes Enrollment in U.S. IDE Pivotal Trial of Simplify® Disc for Two-Level Cervical Disc Replacement Wednesday, November 14th, 2018
Sunnyvale, CA – November 14, 2018 – Simplify Medical Pty Ltd., maker of the Simplify® cervical artificial disc, today announced that it has completed the enrollment and treatment of all patients in its U.S. Inves [...]
LSP raises record €750 million in 10 months for life sciences innovations Monday, November 12th, 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe [...]
Immunic enters into a global option and license agreement with Daiichi Sankyo Monday, November 5th, 2018
Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease   IMU-856 is a new oral treatment option for ulcerative colit [...]
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exp... Thursday, November 1st, 2018
Regulated information – Inside information   92% overall response rate with durability up to 14.4 months in ongoing analysis of Phase 1/2 trial   Updated results from Phase 1/2 trial of cusatuzumab in [...]
Product of LSP’s portfolio company GTX medical restores walking in humans with spinal cord injury Thursday, November 1st, 2018
Amsterdam, The Netherlands, November 1, 2018 – LSP’s portfolio company GTX medical is developing a groundbreaking product to restore walking in spinal cord injury patients. This week, two articles were published i [...]
argenx reports third quarter 2018 financial results and provides business update Thursday, October 25th, 2018
Breda, the Netherlands / Ghent, Belgium, October 25, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treat [...]
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC) Friday, September 28th, 2018
Arimoclomol was well-tolerated in patients with the rare disease NPC The NPC Phase II/III trial top-line results show a treatment benefit of arimoclomol over placebo on the primary endpoint 5-domain NPC Clin [...]
Merus Strengthens Team with Key Appointments Thursday, September 27th, 2018
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP, Investor Relations and Corporate Communications [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund